The new study comes on the heels of a study published in July 2009 that indicated that the use of MegaNatural BP® grape seed extract, in conjunction with lifestyle modification, may effectively lower blood pressure in patients with metabolic syndrome. That protocol from that study, led by C. Tissa Kappagoda M.D., professor of cardiovascular medicine at UC Davis Health System, was so effective that it has since been patented.
The new double blind, placebo controlled studies will also be conducted under the direction of Dr. Kappagoda. The first will measure the inflammatory markers in people who are overweight or diagnosed with metabolic syndrome throughout a full day’s worth of high fat meals. The second will look directly at whether grape seed extract suppresses those inflammatory markers. MegaNatural BP® will be used in that study. Inflammatory markers are associated with insulin resistance, a condition which can develop into Type 2 Diabetes.
“If we can suppress the inflammatory response in a single meal with grape seed extract, then we might be able to give grape seed extract continually to suppress the impact on insulin resistance from frequent high fat meals,” explains Dr. Kappagoda. “This could lead to an opportunity for a larger clinical trial to see if we can at least delay the onset of Type 2 diabetes. It might allow us to buy time to institute other remedial measures with people diagnosed with metabolic syndrome.”
“We are excited that MegaNatural BP is proving to be such an important product in the fight against the devastating effects of metabolic syndrome,” says Dr. Anil Shrikhande, President of Polyphenolics.
Polyphenolics is demonstrating its commitment to educating members of the health and nutrition industry about the significance of antioxidants with its sponsorship of the Antioxidant Science track during Nutracon 2010, taking place March 10-11 in Anaheim. Polyphenolics also will exhibit at SupplyExpo 2010, March 12-14 at the Anaheim Convention Center. They will be in Booth #818.